Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatic Impairment: early-phase trial registry
13 of 49 indexed Hepatic Impairment trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #281 of 28,707 conditions by registered trial count.
49 US clinical trials · 13 currently recruiting · #281 of 28,707 conditions by registered trial count
Hepatic Impairment: 49 US clinical trials tracked, 13 recruiting.
Hepatic Impairment is the subject of 49 registered US clinical trials on ClinicalTrials.gov, 13 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 49 in Phase 1-2 (earlier-stage). The most active sponsor is Pfizer, running 4 of these trials.
Enrollment posture brief
Registry condition hepatic-impairment
OPEN 13 | RECR 27% | LATE 0 | EARLY 49 | RANK #281 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Pulmonary Embolism (27% recruiting · 49 trials)
Hepatic Impairment lists 13 open slots (27% of 49 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatic Impairment on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatic Impairment is recruiting below its size-band peers.
13 of 49 indexed trials (26.5%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hepatic Impairment trials is spread across many organizations.
Pfizer accounts for 4 of 49 trials (8.2%). 38 distinct sponsors appear on at least one study for this condition label.
-
Most Hepatic Impairment trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 49 trials that report a genuine target (sentinel values excluded). 47 of those (95.9%) plan for fewer than 100 participants.
-
Hepatic Impairment research is mostly interventional.
49 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
49 total, page 1 of 1
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
Vir Biotechnology
NCT05484206
A Study of Calderasib (MK-1084) in Participants With Hepatic Impairment and Healthy Volunteers (MK-1084-017)
Merck Sharp & Dohme
NCT07219550
An Investigational Study of ESK-001 in Participants With Normal Liver Function and Participants With Mild, Moderate, and Severe Liver Damage
Alumis
NCT06952634
Phase 1 Open-Label Study of Radiprodil Pharmacokinetics, Safety, and Tolerability in Hepatically Impaired Participants
GRIN Therapeutics
NCT07457229
A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
Boehringer Ingelheim
NCT07023354
Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
SpringWorks Therapeutics
NCT06997276
A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Genentech
NCT07144111
Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
Zydus Therapeutics
NCT05045482
Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
Atea Pharmaceuticals
NCT06911320
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
Pfizer
NCT07269301
A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function
Epizyme
NCT04241835
Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Exelixis
NCT06962332
Assessment of Quizartinib Pharmacokinetic in Subjects With Severe Hepatic Impairment
Daiichi Sankyo
NCT06740799
A Study to Evaluate the Pharmacokinetics of AFQ056 in Subjects With Hepatic Impairment Compared to Healthy Subjects
Novartis Pharmaceuticals
NCT01456663
Hepatic Impairment, Cholestatic Liver Disease, & NASH with Advanced Fibrosis & Normal Hepatic Function
Zydus Therapeutics
NCT04469920
Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control Subjects
Madrigal Pharmaceuticals
NCT04643795
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
Gilead Sciences
NCT05765344
Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
Atea Pharmaceuticals
NCT05724693
A Single-dose, Open-label, Pharmacokinetic Study of Belapectin (GR-MD-02) in Subjects With Normal Hepatic Function and Subjects With Varying Degrees of Hepatic Impairment
Galectin Therapeutics
NCT04332432
Pharmacokinetics and Safety Study of Siremadlin (HDM201) in Participants With Mild, Moderate and Severe Hepatic Impairment
Novartis Pharmaceuticals
NCT05599932
A Study of Soticlestat in Adults With Liver Failure Compared to Those With Normal Liver Function
Takeda
NCT05098054
Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients
Jazz Pharmaceuticals
NCT01887301
Pharmacokinetics of AGO178 in Participants With Liver Impairment
Novartis Pharmaceuticals
NCT01531309
The Effect o f Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Betrixiban, an Oral FXa Antagonist
Portola Pharmaceuticals
NCT03397888
A Trial to Evaluate the Pharmacokinetics of ABL001 in Healthy and Hepatic Impaired Subjects
Novartis Pharmaceuticals
NCT02857868
A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.
Celgene
NCT03290443
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
Insmed Incorporated
NCT05517525
A Study to Evaluate the Effects of Hepatic Impairment on the Pharmacokinetics of Relacorilant
Corcept Therapeutics
NCT06094725
Elafibranor Pharmacokinetic Parameters in Hepatic Impaired Patients
Genfit
NCT03765671
Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Balcinrenone
AstraZeneca
NCT06388616
Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
Vanda Pharmaceuticals
NCT01271387
Study of Single-dose DS-3201b in Participants With Hepatic Impairment
Daiichi Sankyo
NCT04276662
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.
Basilea Pharmaceutica
NCT05582187
A Study to Assess S-217622 in Participants With Mild and Moderate Hepatic Impairment and Healthy Control Participants
Shionogi
NCT05409911
A Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Olpasiran in Participants With Various Degrees of Hepatic Impairment
Amgen
NCT05481411
A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
Akebia Therapeutics
NCT03799848
A Study to Evaluate the Pharmacokinetics of Avacopan (CCX168) in Participants With Mild or Moderate Hepatic Impairment
Amgen
NCT06004934
A Study to Understand How the Study Medicine (PF-07081532) is Processed in People With Liver Dysfunction
Pfizer
NCT05478603
Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Mild and Moderate Hepatic Impairment Compared to Healthy Subjects
Eisai
NCT03440424
Effect Of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of PF-06865571 In Subjects With Hepatic Impairment and in Healthy Subjects
Pfizer
NCT04091061
Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment
Bristol-Myers Squibb
NCT00162097
Pharmacokinetics of Sotorasib in Healthy Participants and Participants With Moderate or Severe Hepatic Impairment
Amgen
NCT04887064
Tepotinib Hepatic Impairment Trial
EMD Serono Research & Development Institute
NCT03546608
PK and Safety in Participants Taking Obicetrapib With Moderate Hepatic Impairment Relative to Normal Hepatic Function
NewAmsterdam Pharma
NCT06048302
A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function
Janssen Research & Development
NCT04154774
Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
Pfizer
NCT05005312
A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function
Institut de Recherches Internationales Servier
NCT05674474
Surufatinib Hepatic Impairment Study
Hutchison Medipharma Limited
NCT04755075
Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment
Mylan
NCT02581592
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 49 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatic Impairment records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatic Impairment trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatic Impairment page
49 registered trials, 13 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 13 Hepatic Impairment trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Pfizer sponsors the most Hepatic Impairment trials on record, review their full trial history before evaluating a specific study. See Pfizer's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatic Impairment condition card totals 49 registered trials; most-linked intervention Saroglitazar Magnesium 2 mg; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.